Piper Jaffray Upbeat on MiSeq; Dismisses Rumors of Roche-Illumina Deal | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina's MiSeq platform is best positioned to benefit from the growing interest in desktop sequencing, a Piper Jaffray analyst said today.

In a research note analyst William Quirk also called recent speculation that Roche could be again pursuing the San Diego-based company "ridiculous and unfounded."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.